Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population

• Published in: Medical science monitor Vol. 18; no. 8; pp. CR512 - CR517
• Main Authors: Buzková, Helena, Pechandová, Kristina, Danzig, Vilém, Vareka, Tomá, Perlik, Frantisek, Zak, Ales, Slanar, Ondrej
• Format: Journal Article
• Language: English
• Published: United States International Scientific Literature, Inc 01-08-2012
• Subjects: Adult; Aged; Aged, 80 and over; Alleles; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - pharmacology; Aryl Hydrocarbon Hydroxylases - genetics; Case-Control Studies; Cholesterol - blood; Clinical Research; Cytochrome P-450 CYP2C9; Czechoslovakia; Demography; Fatty Acids, Monounsaturated - adverse effects; Fatty Acids, Monounsaturated - pharmacology; Female; Fluvastatin; Gene Frequency - genetics; Genotype; Humans; Hypercholesterolemia - blood; Hypercholesterolemia - drug therapy; Hypercholesterolemia - genetics; Indoles - adverse effects; Indoles - pharmacology; Male; Middle Aged; Polymorphism, Single Nucleotide - genetics; Prevalence
• ISSN: 1234-1010; 1643-3750
• DOI: 10.12659/MSM.883272

CYP2C9*3 allele has been reported to correlate with increased plasma concentration of fluvastatin active form in healthy volunteers. We analyzed the correlation between the CYP2C9 genotype and cholesterol-lowering effect of fluvastatin in human hypercholesterolemic patients.
The study was prospective, without any interventions to standard procedures of hypolipidemic treatment. CYP2C9 genotype was determined by PCR-RFLP assay in 87 patients on concomitant fluvastatin therapy, in 48 patients on monotherapy, and in a control group of 254 healthy volunteers of Czech nationality. Biochemical and clinical data were collected before the initiation of fluvastatin treatment and 12 weeks later.
The frequency of CYP2C9 alleles did not differ significantly among groups of patients and volunteers. The most frequently observed allele was CYP2C9*2. Treatment with 80 mg of fluvastatin daily of 48 patients on monotherapy for 12 weeks resulted in mean low-density lipoprotein cholesterol (LDL-C) reduction by 25%, mean serum total cholesterol (TC) reduction by 21%, and mean triglyceride (TG) reduction by 28%. The CYP2C9*1/*3 genotype was associated with a decrease in LDL-C levels (by 40.0% for CYP2C9*1/*3, but only by 22.4% for CYP2C9*1/*1), and with the reduction of TC (by 28.6% in CYP2C9*1/*3 versus 20.2% in CYP2C9*1/*1).
In hypercholesterolemic patients, LDL-C serum concentration was decreased more significantly in fluvastatin-treated subjects bearing the CYP2C9*1/*3 genotype compared to CYP2C9*1/*1 genotype. However, due to rare occurrence of some CYP genotypes, it was impossible to report a definitive positive genotype-fluvastatin effect association.